company background image
ALNO

NOXXON Pharma ENXTPA:ALNOX Stock Report

Last Price

€0.12

Market Cap

€10.1m

7D

50.2%

1Y

-71.8%

Updated

28 May, 2022

Data

Company Financials +
ALNOX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ALNOX Stock Overview

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.

NOXXON Pharma Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for NOXXON Pharma
Historical stock prices
Current Share Price€0.12
52 Week High€0.52
52 Week Low€0.061
Beta2.08
1 Month Change32.60%
3 Month Change-36.17%
1 Year Change-71.77%
3 Year Change-84.21%
5 Year Change-99.30%
Change since IPO-99.44%

Recent News & Updates

Shareholder Returns

ALNOXFR BiotechsFR Market
7D50.2%-0.4%3.7%
1Y-71.8%-39.4%-3.7%

Return vs Industry: ALNOX underperformed the French Biotechs industry which returned -39.4% over the past year.

Return vs Market: ALNOX underperformed the French Market which returned -3.7% over the past year.

Price Volatility

Is ALNOX's price volatile compared to industry and market?
ALNOX volatility
ALNOX Average Weekly Movement23.2%
Biotechs Industry Average Movement8.8%
Market Average Movement5.9%
10% most volatile stocks in FR Market9.8%
10% least volatile stocks in FR Market3.4%

Stable Share Price: ALNOX is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: ALNOX's weekly volatility has increased from 15% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199713Aram Mangasarianhttps://www.noxxon.com

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy.

NOXXON Pharma Fundamentals Summary

How do NOXXON Pharma's earnings and revenue compare to its market cap?
ALNOX fundamental statistics
Market Cap€10.11m
Earnings (TTM)-€14.45m
Revenue (TTM)€33.00k

307.7x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALNOX income statement (TTM)
Revenue€33.00k
Cost of Revenue€0
Gross Profit€33.00k
Other Expenses€14.49m
Earnings-€14.45m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.17
Gross Margin100.00%
Net Profit Margin-43,793.94%
Debt/Equity Ratio53.7%

How did ALNOX perform over the long term?

See historical performance and comparison

Valuation

Is NOXXON Pharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.24x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALNOX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALNOX's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ALNOX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.

PE vs Market: ALNOX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALNOX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALNOX is good value based on its Price-To-Book Ratio (2.2x) compared to the FR Biotechs industry average (2.8x).


Future Growth

How is NOXXON Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


123.4%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ALNOX's forecast earnings growth is above the savings rate (0.3%).

Earnings vs Market: Insufficient data to determine if ALNOX's earnings are forecast to grow faster than the French market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ALNOX's revenue (123.4% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: ALNOX's revenue (123.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALNOX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has NOXXON Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-10.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALNOX is currently unprofitable.

Growing Profit Margin: ALNOX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALNOX is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.

Accelerating Growth: Unable to compare ALNOX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALNOX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: ALNOX has a negative Return on Equity (-321.04%), as it is currently unprofitable.


Financial Health

How is NOXXON Pharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALNOX's short term assets (€9.7M) exceed its short term liabilities (€5.3M).

Long Term Liabilities: ALNOX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: ALNOX has more cash than its total debt.

Reducing Debt: ALNOX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALNOX has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: ALNOX is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.


Dividend

What is NOXXON Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALNOX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALNOX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALNOX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALNOX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALNOX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Aram Mangasarian (51 yo)

6.83yrs

Tenure

€585,864

Compensation

Dr. Aram Mangasarian, PhD, has been the Chief Executive Officer and Member of Executive Board at NOXXON Pharma N.V. (formerly known as NOXXON Pharma AG) since July 1, 2015 and served as its has been Chief...


CEO Compensation Analysis

Compensation vs Market: Aram's total compensation ($USD627.67K) is above average for companies of similar size in the French market ($USD285.89K).

Compensation vs Earnings: Aram's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ALNOX's management team is seasoned and experienced (5 years average tenure).


Board Members

Experienced Board: ALNOX's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.7%.


Top Shareholders

Company Information

NOXXON Pharma N.V.'s employee growth, exchange listings and data sources


Key Information

  • Name: NOXXON Pharma N.V.
  • Ticker: ALNOX
  • Exchange: ENXTPA
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €10.106m
  • Shares outstanding: 84.22m
  • Website: https://www.noxxon.com

Number of Employees


Location

  • NOXXON Pharma N.V.
  • Max-Dohrn-Strasse 8-10
  • Berlin
  • Berlin
  • 10589
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/28 00:00
End of Day Share Price2022/05/27 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.